Multiomics analysis identifies oxidative phosphorylation as a cancer vulnerability arising from myristoylation inhibition.
Erwan BeauchampJay M GammaChristopher R CromwellEman W MoussaRony PainMorris A KostiukClaudia Acevedo-MorantesAishwarya IyerMegan YapKrista M VincentLynne M PostovitOlivier JulienBasil P HubbardJohn R MackeyLuc G BerthiaumePublished in: Journal of translational medicine (2024)
Targeting of both, oxidative phosphorylation and cell signaling partly explains the lethal effects of zelenirstat in select cancer types. While the prognostic value of the sensitivity score MISS-54 remains to be validated in patients, our findings continue to warrant the clinical development of zelenirstat as cancer treatment.
Keyphrases
- papillary thyroid
- end stage renal disease
- squamous cell
- ejection fraction
- newly diagnosed
- chronic kidney disease
- lymph node metastasis
- single cell
- prognostic factors
- protein kinase
- stem cells
- cell therapy
- genome wide
- gene expression
- squamous cell carcinoma
- patient reported outcomes
- childhood cancer
- dna methylation
- bone marrow
- drug delivery